{"groups":[{"description":"Patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.\n\nFOLFOX or: Patients receive oxaliplatin 85 mg/m\\^2 IV infused over two hours followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus, then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours\n\nFOLFIRI: Patients receive irinotecan 180 mg/m\\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus following leucovorin then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours.","id":"FG000","title":"Arm A: FOLFOX or FOLFIRI + Bevacizumab"},{"description":"Patients receive cetuximab 400mg/m\\^2 IV over 2 hours on the first day of treatment, then 250 mg/m\\^2 IV over 1 hour weekly thereafter. Patients also receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.\n\nFOLFOX or: Patients receive oxaliplatin 85 mg/m\\^2 IV infused over two hours followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus, then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours\n\nFOLFIRI: Patients receive irinotecan 180 mg/m\\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus following leucovorin then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours.","id":"FG001","title":"Arm B: FOLFOX or FOLFIRI + Cetuximab"},{"description":"Patients receive cetuximab 400mg/m\\^2 IV over 2 hours on the first day of treatment, then 250 mg/m\\^2 IV over 1 hour weekly thereafter. Also, patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.\n\nFOLFOX or: Patients receive oxaliplatin 85 mg/m\\^2 IV infused over two hours followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus, then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours\n\nFOLFIRI: Patients receive irinotecan 180 mg/m\\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus following leucovorin then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours.","id":"FG002","title":"Arm C: FOLFOX or FOLFIRI + Cetuximab + Bevacizumab"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"899"},{"groupId":"FG001","numSubjects":"902"},{"groupId":"FG002","numSubjects":"533"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"899"},{"groupId":"FG001","numSubjects":"902"},{"groupId":"FG002","numSubjects":"533"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"From 5/2005 to 9/2009, patients were randomized 1:1:1 to Arms A, B and C. Study was amended in 2009 to include only KRAS wild type patients; then Arm C was closed based on data showing no benefit from chemo with the combination of Bevacizumab and an EGFR antibody. Thereafter, only KRAS wild type patients were randomized 1:1 to Arm A and B."}